Case Against Generic Paxil Sputters In Appeals Court
On Monday, the Supreme Court let stand a lower court ruling against patent protection for the active ingredient in Paxil, effectively ending Glaxo’s case. On Thursday, the Federal Circuit denied Glaxo’s request that the court rehear a separate patent case related to the process of making a Paxil tablet.
In the case...
To view the full article, register now.